drugset / Trial / NCT02525822

Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris

NCT02525822

Phase 2 Unknown 210 enrolled Valeant Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to compare the safety and efficacy of once daily application of IDP-123 Lotion to Tazorac Cream, 0.1%, Vehicle Lotion, and Vehicle Cream in subjects with moderate to severe acne vulgaris.

Timeline

Start
2015-09
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tazarotene Small molecule 0.1 % Topical
Comparator Tazarotene Small molecule Topical

Indications